Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
41 studies found for:    Open Studies | "Dermatomyositis"
Show Display Options
Rank Status Study
21 Recruiting The CARRA Registry
Conditions: Juvenile Idiopathic Arthritis;   Systemic Lupus Erythematosus;   Mixed Connective Tissue Disease;   Juvenile Ankylosing Spondylitis;   Juvenile Dermatomyositis;   Localized Scleroderma;   Systemic Sclerosis;   Vasculitis;   Sarcoid;   Fibromyalgia, Primary;   Auto-inflammatory Disease;   Idiopathic Uveitis Idiopathic
Intervention:
22 Recruiting Adult and Juvenile Myositis
Conditions: Dermatomyositis;   Polymyositis;   Inclusion Body Myositis
Intervention:
23 Recruiting Diagnostic Accuracy of Whole Body Magnetic Resonance Imaging in Inflammatory Myopathies
Conditions: Myositis;   Polymyositis;   Dermatomyositis;   Myositis, Inclusion Body
Intervention: Procedure: MRI-oriented muscle biopsy
24 Recruiting Investigating Genes in Patients With Polymyositis and Dermatomyositis
Condition: Myositis
Intervention: Procedure: Venepuncture
25 Recruiting Temporal Artery Biopsy vs ULtrasound in Diagnosis of GCA (TABUL)
Condition: Giant Cell Arteritis
Interventions: Procedure: Ultrasound of temporal and axillary arteries;   Procedure: Temporal artery biopsy
26 Recruiting Prospective Follow-up Study of the Aortic Diameter in Patients With Giant Cell Arteritis
Condition: Giant Cell Arteritis
Intervention:
27 Recruiting One-Time DNA Study for Vasculitis
Conditions: Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss);   Giant Cell Arteritis;   Granulomatosis With Polyangiitis (Wegener's);   Microscopic Polyangiitis;   Polyarteritis Nodosa;   Takayasu's Arteritis
Intervention:
28 Recruiting A Study of RoActemra/Actemra (Tocilizumab) in Patients With Giant Cell Arteritis
Condition: Giant Cell Arteritis
Interventions: Drug: prednisone;   Drug: prednisone placebo;   Drug: tocilizumab [RoActemra/Actemra];   Drug: tocilizumab placebo
29 Recruiting American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis
Conditions: Wegener's Granulomatosis;   Microscopic Polyangiitis;   Churg Strauss Syndrome;   Polyarteritis Nodosa;   Giant Cell Arteritis;   Takayasu Arteritis
Intervention:
30 Recruiting Study of the T CD8 Immune Response in Horton's Disease
Condition: Horton's Disease
Interventions: Other: Blood sample drawn into a 5 mL dry tube at the diagnosis and after 3 months of treatment;   Other: 16 blood samples drawn into 6 mL heparinized tubes at the diagnosis and after 3 months of treatment;   Other: Blood sample drawn into a 5 mL dry tube;   Other: 16 blood samples drawn into 6 mL heparinized tubes
31 Not yet recruiting Study of Circulating Microparticles in Giant Cell Arteritis
Conditions: Giant Cell Arteritis;   Acute Phase
Intervention: Other: Blood sample
32 Recruiting Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Horton's Disease: Proof of Concept Study.
Condition: Horton's Disease
Intervention: Drug: corticoids+ tocilizumab 8mg/Kg/month
33 Recruiting Quantitative and Functional Study of TH17 Lymphocytes in Horton's Disease (HD)
Conditions: Horton's Disease;   Infectious Disease;   Neoplasia;   Solid Tumor;   Hemopathy
Interventions: Other: 1 blood sample;   Other: 2 to 3 blood samples (at inclusion, at 3 months and at 6 months in cases of relapse)
34 Recruiting Determining Disease Activity Biomarkers in Individuals With Giant Cell Arteritis
Condition: Temporal Arteritis
Intervention:
35 Recruiting Tocilizumab for Patients With Giant Cell Arteritis
Condition: Giant Cell Arteritis
Interventions: Drug: Tocilizumab + Glucocorticoids (GCs);   Drug: Placebo + Glucocorticoids (GCs)
36 Unknown  Carotid Artery Neovascularization in Takayasu's and Giant Cell Arteritis
Conditions: Takayasu's Arteritis;   Giant Cell Arteritis;   Arteritis;   Vasculitis;   Aortitis
Intervention:
37 Recruiting Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD
Conditions: Interstitial Lung Disease;   Scleroderma;   Idiopathic Inflammatory Myositis;   Mixed Connective Tissue Disease
Interventions: Drug: Rituximab;   Drug: Cyclophosphamide
38 Unknown  Evaluating N-Acetylcysteine in CTD-ILD Treatment
Conditions: Interstitial Lung Disease;   Connective Tissue Disease
Intervention: Drug: N-Acetylcysteine
39 Recruiting Belimumab in Myositis
Condition: Myositis
Intervention: Drug: Belimumab + standard of care (randomized phase)
40 Unknown  A Case-control Study to Assess Risk of Coronary Heart Disease in Idiopathic Inflammatory Myopathy
Condition: Idiopathic Inflammatory Myopathy
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-41) Show next page of results    Last Page
Indicates status has not been verified in more than two years